Nature Medicine
September 2026
Stefan Roepke, Nikola Schoofs, Kathlen Priebe et al.
Nightmares are a hallmark of post-traumatic stress disorder (PTSD), yet pharmacological treatments remain limited. Here we conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of dronabinol (BX-1; Δ9-tetrahydrocannabinol (THC)) for PTSD-related nightmares. Adults with PTSD and recurrent nightmares were randomly assigned to receive...
BMC Psychiatry
January 16, 2026
Leonie Ascone, Candelaria Mahlke, Nour Tawil et al.
2 citations
In acute psychiatric inpatient settings, where perception is altered and emotional vulnerability is heightened, many facilities use coercive seclusion rooms for safety. This practice has been increasingly criticized for its psychological impact. While architectural guidelines emphasize human-centered and biophilic design to support well-being, empirical evidence on how design features in this...
Neuropsychopharmacology
February 6, 2019
Stjepan Curic, Gregor Leicht, Stephanie Thiebes et al.
Abnormal gamma-band oscillations (GBO) have been frequently associated with the pathophysiology of schizophrenia. GBO are modulated by glutamate, a neurotransmitter, which is continuously discussed to shape the complex symptom spectrum in schizophrenia. The current study examined the effects of ketamine, a glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist, on the auditory-evoked...
Neuropsychopharmacology
February 5, 2018
Stephanie Thiebes, Saskia Steinmann, Stjepan Curic et al.
Auditory verbal hallucinations (AVH) are a common positive symptom of schizophrenia. Excitatory-to-inhibitory (E/I) imbalance related to disturbed N-methyl-D-aspartate receptor (NMDAR) functioning has been suggested as a possible mechanism underlying altered connectivity and AVH in schizophrenia. The current study examined the effects of ketamine, a NMDAR antagonist, on glutamate-related...
Fortschritte der Neurologie · Psychiatrie
July 1, 2017
Tomislav Majić, Henrik Jungaberle, Timo Torsten Schmidt et al.
10 citations
Zusammenfassung Hintergrund Der Einsatz von serotonergen Halluzinogenen (Psychedelika) wie Lysergsäure-Diethylamid (LSD) und Psilocybin und Entaktogenen wie 3,4-Methylendioxymethamphetamin (MDMA) im Rahmen von Psychotherapie ist in den letzten Jahren wieder zunehmend ins Licht des wissenschaftlichen Interesses gerückt. Die vorliegende Arbeit fasst die aktuelle Evidenz zur substanzunterstützten...
Journal of Psychiatry and Neuroscience
June 1, 2017
Stephanie Thiebes, Gregor Leicht, Stjepan Curic et al.
Background: Targeting the N-methyl-D-aspartate receptor (NMDAR) is a major translational approach for treating negative symptoms of schizophrenia. Ketamine comprehensively produces schizophrenia-like symptoms, such as positive, cognitive and negative symptoms in healthy volunteers. The amplitude of the mismatch negativity (MMN) is known to be significantly reduced not only in patients with...
Journal of Psychopharmacology
February 9, 2015
Tomislav Majić, Timo T Schmidt, Jürgen Gallinat
267 citations
Interest in the therapeutic potential of psychedelic substances has recently resumed. During an early phase of human psychedelic research, their therapeutic application in different pathologies had been suggested, and the first evidence for efficacy was provided. The range of recent clinical applications of psychedelics spans from cluster headaches and obsessive-compulsive disorder to addiction...
Neuroscience Letters
May 27, 2011
Andreas M Stadelmann, Georg Juckel, Larissa Arning et al.
Numerous studies demonstrated a close relationship between cannabis abuse and schizophrenia with similar impairments in cognitive processing, particularly in P300 generation. Recently, an (AAT)n triplet repeat polymorphism within the cannabinoid receptor gene CNR1 has been found to be associated with both schizophrenia and substance dependence, and to modulate the P300 potential. As previously...
European Archives of Psychiatry and Clinical Neuroscience
August 2009
Patrik Roser, Jürgen Gallinat, Gordon Weinberg et al.
Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid...